KaydedilenlerDerginizi ekleyin

Dergiler / Dicle Tıp Dergisi / 2026 / Cilt: 46 Sayı: 3

Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder

Mehmet Solakhan0000-0001-9123-9196
Burak Bilgin0000-0001-6332-2371
Sayfa
429–434
Yayın Tarihi
2019-09-16
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Objective: We aimed to test ocular and systemic safety of mirabegron medication in the treatment of overactive bladder in elderly patients. 

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: We aimed to test ocular and systemic safety of mirabegron medication in the treatment of overactive bladder in elderly patients. 
📊
Temel Bulgular & Veri:Objective: We aimed to test ocular and systemic safety of mirabegron medication in the treatment of overactive bladder in elderly patients. 
💡
Sonuç & Katkı:Objective: We aimed to test ocular and systemic safety of mirabegron medication in the treatment of overactive bladder in elderly patients. 
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Overactive bladder · β3-adrenoreceptor agonist · Oculer safety.

Özet

Objective: We aimed to test ocular and systemic safety of mirabegron medication in the treatment of overactive bladder in elderly patients. 

🔖

Bu Makaleye Atıf Yap

Solakhan, M., Bilgin, B. (2019). Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder. Dicle Tıp Dergisi, Cilt: 46 Sayı: 3, 429–434. https://doi.org/10.5798/dicletip.620366

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (19)

  1. Chapel CR, Amarenco G, Lopez Aramburu MA, et all. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn 2013; 32: 1116-22.
  2. Thiagamoorthy G, Kotes S, Zacche M, et all. The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder. TherAdv Urol 2016; 8: 38-46.
  3. Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf 2003; 26: 749–67.
  4. Tarcan T, Mangır N, Özgür MÖ, et all. OAB-V8 Aşırı aktif mesane sorgulama formu validasyon çalışması. Üroloji Bülteni 2012; 21: 113-16.
  5. Geyer O, Bar-Ilan, A., Nachman, R, et all. Beta3-adrenergic relaxation of bovine iris sphincter. FEBS Lett 1998; 429: 356–8.
  6. Diebold Y, Rios J.D, Hodges R.R, et all. Presence of nerves and their receptors in mouse and human conjunctival goblet cells. Invest. Ophthalmol. Vis. Sci 2001; 42: 2270–82.
  7. Mori A, Miwa T, Sakamoto K, et all. Pharmacological evidence for the presence of functional ocular safety of mırabegron ın healthy volunteers 679 beta (3)-adrenoceptors in rat retinal blood vessels. Naunyn Schmiedebergs Arch Pharmacol 2010; 382: 119–126. Steinle J.J, Zamora D.O, Rosenbaum J.T, Granger H.J. Beta 3-adrenergic receptors mediate choroidal endothelial cell invasion, proliferation, and cell elongation. Exp. Eye Res 2005; 80: 83–91.
  8. Lee C-L, Kuo H-C. Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility. Lower Urinary Tract Symptoms 2019; 11: 93-97. https://doi.org/10.1111/luts.12224.
  9. Gray SL, Anderson ML, Dublin S, et all. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175: 401–7.
  10. Chapple C, DuBeau C, Ebinger U, et all. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007; 23:2347–58.
  11. Wagg A, Arumi D, Herschorn S, et all. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older. Age Ageing 2017; 46: 620–6.
  12. Chapple CR, Kaplan SA, Mitcheson D, et all. Randomized doubleblind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β (3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013; 63: 296–305.
  13. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987–1006.
  14. Sung VC, Corridan PG. Acute-angle closure glaucoma as a sideeffect of oxybutynin. Br J Urol 1998; 81: 634–5.
  15. Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf 2003; 26: 749–67.
  16. Turkoglu AR, Yener NP, Coban S, Guzelsoy M, Demirbas M, Demirci H. Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder. Int Urogynecol J 2017; 28: 777-81. doi: 10.1007/s00192-016-3199-x. Epub 2016 Nov 14.
  17. Garely AD, Kaufman JM, Sand PK, et all. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). ClinTher 2006; 28: 1935–46.
  18. Nambiar AK, Bosch R, Cruz F, et all. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. Eur Urol 2018; 73: 596-609. Doi: 10.1016/j.eururo.2017.12.031. Epub 2018 Feb
  19. Chapple C, DuBeau C, Ebinger U, et all. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007; 23:2347–58.